Literature DB >> 21764858

Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer.

John V Heymach1, Terry J Shackleford, Hai T Tran, Suk-Young Yoo, Kim-Anh Do, Melanie Wergin, Pierre Saintigny, Robin T Vollmer, Thomas J Polascik, Denise C Snyder, Mack T Ruffin, Shaoyu Yan, Mark Dewhirst, Ajaikumar B Kunnumakkara, Bharat B Aggarwal, Wendy Demark-Wahnefried.   

Abstract

Diet, nutritional status, and certain dietary supplements are postulated to influence the development and progression of prostate cancer. Angiogenesis and inflammation are central to tumor growth and progression, but the effect of diet on these processes remains uncertain. We explored changes in 50 plasma cytokines and angiogenic factors (CAF) in 145 men with prostate cancer enrolled in a preoperative, randomized controlled phase II trial with four arms: control (usual diet), low-fat (LF) diet, flaxseed-supplemented (FS) diet, and FS+LS diet. The mean duration of dietary intervention was 30 to 31 days. Among the individual arms, the largest number of significant changes (baseline vs. preoperative follow-up) was observed in the LF arm, with 19 CAFs decreasing and one increasing (P < 0.05). Compared with the control arm, 6 CAFs-including proangiogenic factors (stromal-cell derived-1α) and myeloid factors (granulocyte-colony-stimulating factor, macrophage colony-stimulating factor)-all decreased in the LF arm compared with controls; three and four CAFs changed in the FS and FS+LF arms, respectively. Weight loss occurred in the LF arms and significantly correlated with VEGF decreases (P < 0.001). The CAFs that changed in the LF arm are all known to be regulated by NF-κB, and a pathway analysis identified NF-κB as the most likely regulatory network associated with these changes in the LF arm but not in the FS-containing arms. These results suggest that a LF diet without flaxseed may reduce levels of specific inflammatory CAFs and suggests that the NF-κB pathway may be a mediator of these changes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764858      PMCID: PMC3438697          DOI: 10.1158/1940-6207.CAPR-10-0136

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  53 in total

Review 1.  Phytoestrogens and prostate disease.

Authors:  H Adlercreutz; W Mazur; P Bartels; V Elomaa; S Watanabe; K Wähälä; M Landström; E Lundin; A Bergh; J E Damber; P Aman; A Widmark; A Johansson; J X Zhang; G Hallmans
Journal:  J Nutr       Date:  2000-03       Impact factor: 4.798

2.  Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

Authors:  Li-Hua Chen; Jing Fang; Zhijian Sun; Huaixing Li; Ying Wu; Wendy Demark-Wahnefried; Xu Lin
Journal:  J Nutr       Date:  2009-02-11       Impact factor: 4.798

3.  Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis.

Authors:  Q X Zhang; C J Magovern; C A Mack; K T Budenbender; W Ko; T K Rosengart
Journal:  J Surg Res       Date:  1997-02-01       Impact factor: 2.192

4.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors:  Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  Adipose tissue mass can be regulated through the vasculature.

Authors:  Maria A Rupnick; Dipak Panigrahy; Chen-Yu Zhang; Susan M Dallabrida; Bradford B Lowell; Robert Langer; M Judah Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

6.  Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways.

Authors:  Chun-Yin Huang; Chun-Yi Lee; Meng-Yi Chen; Wei-Hung Yang; Ying-Hao Chen; Chia-Hao Chang; Horng-Chaung Hsu; Yi-Chin Fong; Chih-Hsin Tang
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

7.  Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity.

Authors:  Joan Vendrell; Montserrat Broch; Nuria Vilarrasa; Ana Molina; Jose Manuel Gómez; Cristina Gutiérrez; Immaculada Simón; Joan Soler; Cristóbal Richart
Journal:  Obes Res       Date:  2004-06

8.  Circulating mononuclear cells in the obese are in a proinflammatory state.

Authors:  Husam Ghanim; Ahmad Aljada; Deborah Hofmeyer; Tufail Syed; Priya Mohanty; Paresh Dandona
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690

9.  Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.

Authors:  Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

Review 10.  Obesity, metabolic syndrome, and prostate cancer.

Authors:  Ann W Hsing; Lori C Sakoda; Streamson Chua
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

View more
  22 in total

Review 1.  Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Authors:  Maria Hernandez-Yanez; John V Heymach; Amado J Zurita
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer.

Authors:  James R Hébert; Thomas G Hurley; Brook E Harmon; Sue Heiney; Christine J Hebert; Susan E Steck
Journal:  Cancer Epidemiol       Date:  2011-10-20       Impact factor: 2.984

Review 3.  Obesity, energy balance, and cancer: new opportunities for prevention.

Authors:  Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-03

Review 4.  Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Authors:  Keith I Block; Charlotte Gyllenhaal; Leroy Lowe; Amedeo Amedei; A R M Ruhul Amin; Amr Amin; Katia Aquilano; Jack Arbiser; Alexandra Arreola; Alla Arzumanyan; S Salman Ashraf; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan Bilsland; Anupam Bishayee; Stacy W Blain; Penny B Block; Chandra S Boosani; Thomas E Carey; Amancio Carnero; Marianeve Carotenuto; Stephanie C Casey; Mrinmay Chakrabarti; Rupesh Chaturvedi; Georgia Zhuo Chen; Helen Chen; Sophie Chen; Yi Charlie Chen; Beom K Choi; Maria Rosa Ciriolo; Helen M Coley; Andrew R Collins; Marisa Connell; Sarah Crawford; Colleen S Curran; Charlotta Dabrosin; Giovanna Damia; Santanu Dasgupta; Ralph J DeBerardinis; William K Decker; Punita Dhawan; Anna Mae E Diehl; Jin-Tang Dong; Q Ping Dou; Janice E Drew; Eyad Elkord; Bassel El-Rayes; Mark A Feitelson; Dean W Felsher; Lynnette R Ferguson; Carmela Fimognari; Gary L Firestone; Christian Frezza; Hiromasa Fujii; Mark M Fuster; Daniele Generali; Alexandros G Georgakilas; Frank Gieseler; Michael Gilbertson; Michelle F Green; Brendan Grue; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Patricia Hentosh; Matthew D Hirschey; Lorne J Hofseth; Randall F Holcombe; Kanya Honoki; Hsue-Yin Hsu; Gloria S Huang; Lasse D Jensen; Wen G Jiang; Lee W Jones; Phillip A Karpowicz; W Nicol Keith; Sid P Kerkar; Gazala N Khan; Mahin Khatami; Young H Ko; Omer Kucuk; Rob J Kulathinal; Nagi B Kumar; Byoung S Kwon; Anne Le; Michael A Lea; Ho-Young Lee; Terry Lichtor; Liang-Tzung Lin; Jason W Locasale; Bal L Lokeshwar; Valter D Longo; Costas A Lyssiotis; Karen L MacKenzie; Meenakshi Malhotra; Maria Marino; Maria L Martinez-Chantar; Ander Matheu; Christopher Maxwell; Eoin McDonnell; Alan K Meeker; Mahya Mehrmohamadi; Kapil Mehta; Gregory A Michelotti; Ramzi M Mohammad; Sulma I Mohammed; D James Morre; Vinayak Muralidhar; Irfana Muqbil; Michael P Murphy; Ganji Purnachandra Nagaraju; Rita Nahta; Elena Niccolai; Somaira Nowsheen; Carolina Panis; Francesco Pantano; Virginia R Parslow; Graham Pawelec; Peter L Pedersen; Brad Poore; Deepak Poudyal; Satya Prakash; Mark Prince; Lizzia Raffaghello; Jeffrey C Rathmell; W Kimryn Rathmell; Swapan K Ray; Jörg Reichrath; Sarallah Rezazadeh; Domenico Ribatti; Luigi Ricciardiello; R Brooks Robey; Francis Rodier; H P Vasantha Rupasinghe; Gian Luigi Russo; Elizabeth P Ryan; Abbas K Samadi; Isidro Sanchez-Garcia; Andrew J Sanders; Daniele Santini; Malancha Sarkar; Tetsuro Sasada; Neeraj K Saxena; Rodney E Shackelford; H M C Shantha Kumara; Dipali Sharma; Dong M Shin; David Sidransky; Markus David Siegelin; Emanuela Signori; Neetu Singh; Sharanya Sivanand; Daniel Sliva; Carl Smythe; Carmela Spagnuolo; Diana M Stafforini; John Stagg; Pochi R Subbarayan; Tabetha Sundin; Wamidh H Talib; Sarah K Thompson; Phuoc T Tran; Hendrik Ungefroren; Matthew G Vander Heiden; Vasundara Venkateswaran; Dass S Vinay; Panagiotis J Vlachostergios; Zongwei Wang; Kathryn E Wellen; Richard L Whelan; Eddy S Yang; Huanjie Yang; Xujuan Yang; Paul Yaswen; Clement Yedjou; Xin Yin; Jiyue Zhu; Massimo Zollo
Journal:  Semin Cancer Biol       Date:  2015-12       Impact factor: 15.707

5.  Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions.

Authors:  Dean E Brenner; Ernest Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2013-01-18

6.  Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.

Authors:  Maria Azrad; Robin T Vollmer; John Madden; Mark Dewhirst; Thomas J Polascik; Denise C Snyder; Mack T Ruffin; Judd W Moul; Dean E Brenner; Wendy Demark-Wahnefried
Journal:  J Med Food       Date:  2013-04       Impact factor: 2.786

Review 7.  Effects of psycho-behavioral interventions on immune functioning in cancer patients: a systematic review.

Authors:  Guixian Tong; Qingqing Geng; Jing Cheng; Jing Chai; Yi Xia; Rui Feng; Lu Zhang; Debin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-14       Impact factor: 4.553

8.  Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Lee W Jones; Diane R Fels; Miranda West; Jason D Allen; Gloria Broadwater; William T Barry; Lee G Wilke; Elisabeth Masko; Pamela S Douglas; Rajesh C Dash; Thomas J Povsic; Jeffrey Peppercorn; P Kelly Marcom; Kimberly L Blackwell; Gretchen Kimmick; Timothy G Turkington; Mark W Dewhirst
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-10

9.  Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.

Authors:  Michael A Liss; Osamah Al-Bayati; Jonathan Gelfond; Martin Goros; Sarah Ullevig; John DiGiovanni; Jill Hamilton-Reeves; Denise O'Keefe; Dean Bacich; Brandi Weaver; Robin Leach; Ian M Thompson
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-11-01       Impact factor: 5.554

10.  Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.

Authors:  Pierre-Olivier Gaudreau; Marcelo V Negrao; Kyle G Mitchell; Alexandre Reuben; Erin M Corsini; Jun Li; Tatiana V Karpinets; Qi Wang; Lixia Diao; Jing Wang; Lorenzo Federico; Edwin R Parra-Cuentas; Roohussaba Khairullah; Carmen Behrens; Arlene M Correa; Daniel Gomez; Latasha Little; Curtis Gumbs; Humam N Kadara; Junya Fujimoto; Daniel J McGrail; Ara A Vaporciyan; Stephen G Swisher; Garrett Walsh; Mara B Antonoff; Annikka Weissferdt; Hai Tran; Emily Roarty; Cara Haymaker; Chantale Bernatchez; Jianhua Zhang; P Andrew Futreal; Ignacio I Wistuba; Tina Cascone; John V Heymach; Boris Sepesi; Jianjun Zhang; Don L Gibbons
Journal:  J Thorac Oncol       Date:  2020-10-21       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.